-+ 0.00%
-+ 0.00%
-+ 0.00%

*Xilio Therapeutics Sees Delivering Phase 1/2 Option Data Package to Gilead for Efarindodekin Alfa Program in 1H of 2027 >XLO

Dow Jones·01/08/2026 13:37:00

Please log in to view news